Title | beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia. |
Publication Type | Journal Article |
Year of Publication | 2006 |
Authors | Lee JWon, Chen Q, Knowles DM, Cesarman E, Y Wang L |
Journal | J Mol Diagn |
Volume | 8 |
Issue | 3 |
Pagination | 385-9 |
Date Published | 2006 Jul |
ISSN | 1525-1578 |
Keywords | Benzamides, Fusion Proteins, bcr-abl, Gene Expression, Glucuronidase, Humans, Imatinib Mesylate, K562 Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Molecular Diagnostic Techniques, Neoplasm, Residual, Piperazines, Polymerase Chain Reaction, Pyrimidines, Reference Standards, Sample Size |
Abstract | Quantitative monitoring of breakpoint cluster region (BCR)-Abelson kinase (ABL) transcripts has become indispensable in the clinical care of patients with chronic myelogenous leukemia. Because quantity and quality of RNA in clinical samples are highly variable, a suitable internal normalization control is required for accurate BCR-ABL quantification. However, few studies have examined suitability of the control genes using criteria relevant to residual disease testing. In this study, we evaluated a number of control genes with the application of several novel criteria, including control gene performance on serial patient sample testing and in a residual disease model. We also examined expression of the control genes in BCR-ABL-positive K562 cells in response to Gleevec treatment. We found that beta-glucuronidase is the best control gene among those studied. Importantly, ABL, a widely used control gene, generates misleading BCR-ABL changes that potentially affect the clinical management of chronic myelogenous leukemia patients. |
DOI | 10.2353/jmoldx.2006.050150 |
Alternate Journal | J Mol Diagn |
PubMed ID | 16825513 |
PubMed Central ID | PMC1867607 |
Related Faculty:
Ethel Cesarman, M.D., Ph.D.